Celestica reported strong financial results for 2025, with revenue growing 28% and earnings per share (EPS) increasing by 56%, mainly due to expansion in its CCS segment and rising demand from hyperscaler AI customers. The CCS segment now accounts for about 74% of total revenue, increasing the company's reliance on hyperscaler spending cycles and a concentrated customer base. Management plans to invest $1 billion in capital expenditures in 2026, signaling a shift to a more capital-intensive, infrastructure-like business model. The stock currently trades at around 34 times forward earnings, implying expectations of sustained growth near 40% through 2027, which may limit upside potential if execution or demand falters.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Thor Explorations produced 19,153 ounces of gold in Q2 2026 from its Segilola mine in Nigeria, maintaining its full-year production guidance of 75,000 to 85,000 ounces. The company generated $77.3 million in revenue by selling 17,050 ounces at an ave...
Angelini Pharma has finalized its $4.1 billion acquisition of Catalyst Pharmaceuticals, enhancing its footprint in the U.S. market and strengthening its global leadership in brain health and rare diseases. The deal includes significant investments fr...
Zcash (ZEC) has gained over 16% in the past week, rallying from lows near $368 to around $552 following an 11% jump in one session. This surge is driven by anticipation of the Ironwood shielded pool upgrade expected around July 28, which addresses a ...
Greenwich LifeSciences is developing GLSI-100, an immunotherapy targeting HER2-positive breast cancer, currently in Phase 3 trials. The drug showed a 70-80% reduction in cancer recurrence in Phase 2b, outperforming existing treatments with no serious...
